Cramer's Morning Take: Eli Lily 5/1/25
Squawk on the Street
00:00
Market Dynamics and Investment Strategies for Eli Lilly
This chapter explores Eli Lilly's financial results and the competitive landscape following CVS's partnership with Novo Nordisk for Wegovy. It also evaluates the potential of Eli Lilly's obesity pill, Orphaglipron, and provides investment strategies for navigating recent stock fluctuations.
Transcript
Play full episode
